These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3645956)

  • 21. Critical therapeutic categories: a contraindication to generic substitution?
    Colaizzi JL; Lowenthal DT
    Clin Ther; 1986; 8(4):370-9. PubMed ID: 3731208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Views of Louisiana pharmacists on drug product selection.
    Iyriboz Y; Church G
    J La State Med Soc; 1986 Nov; 138(11):41-5. PubMed ID: 3794682
    [No Abstract]   [Full Text] [Related]  

  • 23. Benefits and liabilities of generic prescribing.
    Lee AM
    W V Med J; 1972 Jun; 68(6):161-6. PubMed ID: 4504384
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug product equivalence--are specifications necessary?
    Bergen JV
    J Am Pharm Assoc; 1972 Jan; 12(1):21-5. PubMed ID: 5007259
    [No Abstract]   [Full Text] [Related]  

  • 25. How good are our drugs?
    Miller LC
    Am J Hosp Pharm; 1970 May; 27(5):367-74. PubMed ID: 5422276
    [No Abstract]   [Full Text] [Related]  

  • 26. Keeping up with drug safety information.
    Meadows M
    FDA Consum; 2006; 40(3):38-9. PubMed ID: 16906667
    [No Abstract]   [Full Text] [Related]  

  • 27. Substitution of NTI drugs: physicians must maintain control.
    Todd JS
    J Med Assoc Ga; 1997 Apr; 86(2):121-3. PubMed ID: 9114660
    [No Abstract]   [Full Text] [Related]  

  • 28. [Clinical testing of drugs].
    Elis J
    Cesk Zdrav; 1973; 21(3):126-30. PubMed ID: 4580127
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharma's year of trouble and strife.
    Frantz S
    Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339
    [No Abstract]   [Full Text] [Related]  

  • 30. LyphoMed sparks worries.
    Wagner M
    Mod Healthc; 1988 Jul; 18(29):5. PubMed ID: 10325202
    [No Abstract]   [Full Text] [Related]  

  • 31. Bioequivalence studies: a new EMA guideline.
    Houin G
    Arzneimittelforschung; 2010; 60(4):169-70. PubMed ID: 20486464
    [No Abstract]   [Full Text] [Related]  

  • 32. Quality drugs and the Saskatchewan formulary.
    Johnson GE
    Can J Hosp Pharm; 1975; 28(3):84-6. PubMed ID: 10316621
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmaceutical counterfeiting.
    Deisingh AK
    Analyst; 2005 Mar; 130(3):271-9. PubMed ID: 15724152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy.
    Verbeeck RK; Kanfer I; Walker RB
    Eur J Pharm Sci; 2006 May; 28(1-2):1-6. PubMed ID: 16413762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generic drugs.
    Med Lett Drugs Ther; 1999 May; 41(1053):47-8. PubMed ID: 10368699
    [No Abstract]   [Full Text] [Related]  

  • 36. Brand or generic?
    J Okla Dent Assoc; 2003; 93(3):12. PubMed ID: 12674709
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. QUAD routes out inferior drugs.
    Can Hosp; 1973 May; 50(5):58-9. PubMed ID: 4779804
    [No Abstract]   [Full Text] [Related]  

  • 39. What's best for the patient?
    Burkle WS
    Am J Hosp Pharm; 1983 Apr; 40(4):558. PubMed ID: 6846359
    [No Abstract]   [Full Text] [Related]  

  • 40. [Pharmacological ethnic metabolic safety. Communication I].
    Piruzian LA; Mikhaĭlovskiĭ EM
    Fiziol Cheloveka; 2003; 29(2):118-26. PubMed ID: 12751231
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.